COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics.

Emerging evidence on SGLT2 inhibitors' impact on CKD outcomes is vital for nephrologists managing diabetic and non-diabetic patients.